Kornimate/medical-research-clean huggingface dataset:
a study to evaluate the efficacy and safety of a sintilimab plus ice regimen versus ice regimen in classic hodgkin's lymphoma patients (chl) who have failed first-line standard chemotherapy

Conditions: Classic Hodgkin's Lymphoma

Summary: this phase iii trial studies the side effects of sintilimab to see how well it works when given together with ifosfamide, carboplatin, and etoposide in treating patients with classic hodgkin lymphoma that does not respond to first-line standard chemotherapy.

randomized, double-blind, two arms , multicenter

Eligibility criteria:
inclusion criteria: 1. signed informed consent 2. histopathologically confirmed chl 3. failed first-line standard combination chemotherapy 4. one measurable lesion (lugano 2014) 5. eastern cooperative oncology group (ecog) of 0-1 6. male or female aged ≥18 years 7. patients must have adequate organ and bone marrow function exclusion criteria: 1. patients must not have known central nervous system (cns) involvement 2. patients must not have had prior exposure to any immune checkpoint inhibitors including anti-pd-l1 agents, anti-pd-l2 agents, or anti-ctla-4 monoclonal antibodies 3. patients may not simultaneously participate in another interventional clinical study 4. patients may not receive any other investigational agents within 4 weeks of study registration 5. patients may not receive any other form of immunosuppressive therapy within 4 weeks prior to the first dose of study drug 6. patients may not receive live attenuated vaccines within 4 weeks prior to the first dose of study drug (or plan to receive live attenuated vaccines during the study period) 7. patients with known immunodeficiency are ineligible 8. patients with known active tb (bacillus tuberculosis) are ineligible 9. patients must not have had prior allogeneic stem cell transplantation or allogeneic organ transplantation 10. patients must not be pregnant or breastfeeding
cambridge 7 tesla cerebral small vessel disease study

Conditions: Cerebral Small Vessel Diseases; Cerebral Small Vessel Ischemic Disease; Lacunar Stroke

Summary: camsvd is jointly sponsored by the university of cambridge and cambridge university hospitals nhs foundation trust. we aim to explore and understand the underlying arterial pathology in cerebral small vessel disease (svd) using ultra-high-field 7 tesla mri. we will optimise 7t time-of-flight mr angiography, blood suppressed mr sequence and phase-contrast (pc) mr angiography for visualization of perforating lenticulostriate arteries. this optimised sequences will be used to determine the range of arterial pathologies seen in individuals presenting with lacunar strokes. the pathologies of the perforating lenticulostriate arteries will be correlated with conventional clinical risk factors, cognition and radiological markers of svd.


Eligibility criteria:
inclusion criteria: 1. symptomatic lacunar stroke with corresponding lacunar infarct on mri exclusion criteria: 1. unable/unwilling to consent; 2. age\<18; 3. stroke aetiology due to cardio-embolism or large vessel disease; 4. lacunar infarcts \>1.5cm; 5. severe stroke (nihss score ≥16); 6. evidence of cortical infarct of any size; 7. other major neurological diseases; 8. severe systemic diseases such as heart failure, liver failure and kidney failure or any illness in the judgement of the investigator that could affect participation in the study; 9. mri contraindications e.g. metal objects in or on the body, claustrophobia, pregnancy, known allergy to gadolinium containing contrast agent, impaired renal function with estimated glomerular filtration rate (egfr) \<59ml/min/1.73m2.

Keywords: vascular cognitive impairment vascular dementia 7 tesla magnetic resonance imagine (7t mri)
towards novel biomarkers to diagnose sepsis on the emergency room

Conditions: Sepsis; Septic Shock; Sepsis, Severe; Infections; Infection Viral; Infection, Bacterial; Infections, Respiratory

Summary: objectives: 1. to compare the immune response of patients with or without sepsis presenting to the ed with a(n) (suspected) infection. 2. to determine immune response aberrations that are associated with an increased risk of developing sepsis in patients presenting to the ed with a(n) (suspected) infection without sepsis. 3. to determine the long term cognitive and physical sequelae of sepsis after admission.

sepsis will be defined in accordance with the current sepsis 3.0 criteria as a(n) (suspected) infection with evidence of organ failure, as reflected by a sofa (sequential organ failure assessment) score of ≥2. notably, a molecular definition of sepsis does not exist and there is no pathological gold standard; therefore, in accordance with the current international consensus, the investigators consider the commonly used clinical organ failure (sofa) criteria as the best option. the sofa score is composed of six organ dysfunctions (cardiovascular, pulmonary, renal, hepatic, coagulation and neurological). the sofa score was developed for icu patients, but its components can be easily scored in an ed (and hospital ward) setting with the exception of the pulmonary component; this pulmonary dysfunction score is based on the pao2/fio2 (pf) ratio, wherein pao2 is the partial pressure of oxygen in arterial blood and fio2 the fraction of inspired oxygen. measurement of the pao2 requires an arterial blood puncture, which is not routinely done on the er or hospital ward. therefore, the investigators will use an alternative method to determine the respiratory sofa by determining the spo2/fio2 (sf) ratio, wherein spo2 is peripheral oxygen saturation. spo2 is routinely measured by finger pulse oximeter in patients with suspected infection; fio2 is 21% when breathing room temperature and increases by 4% with each liter of oxygen provided per minute to a patient via a nasal cannula. cut-off values for sf ratios correlating with sofa pulmonary scores based on pf ratios have been validated in large data sets.

Eligibility criteria:
inclusion criteria: * age 18 years or higher * presentation at the emergency department (ed) * clinical suspicion of infection or earlier confirmed infection * modified early warning score (mews) of 2 or higher exclusion criteria: * no informed consent given

Keywords: biomarkers emergency room a&e accident & emergency
pericapsular nerve group block versus caudal block for postoperative pain management in pediatric hip surgery

Conditions: Pain, Postoperative

Summary: children can experience substantial pain after hip operations, causing agitation, depression, and sleep disruption, which can have a negative impact on their health. opioids are associated with several serious side effects that limits its use as solo agents for pain management. regional blocks such as caudal block (cb) and pericapsular nerve group (peng) block in adjuvant with general anaesthesia are alternative perioperative analgesic techniques that lead to lesser side effects, including motor weakness, postoperative nausea and vomiting with decreased opioid consumption.

regional anesthesia is often used to prevent postoperative pain in pediatric surgery. combined with general anesthesia (ga), ultrasound (us)-guided regional anesthetic approaches provide simple intraoperative pathway that reduced ga requirements, lower pain score with less impact on the respiratory or cardiovascular system in pediatric surgery, caudal block (cb) is a low-cost, simple, and effective procedure for postoperative analgesia. cb is suggested for most surgeries in the lower body, primarily below the umbilicus. although the well-established anesthetic properties of cb, its action terminates early in the postoperative period and it has a number of restrictions, such as anatomical abnormalities or infection at the injection site, that can prevent its use peng block is the plane lying between the psoas muscle and tendon and the ilio-pubic eminence. the single-shot peng block has lately been reported in the cadaveric study and in the literature for perioperative pain management in hip surgery by aiming the articular arms of the accessory obturator nerve (aon), femoral nerve (fn), and obturator nerve (on). the technical simplicity of imaging in traction-fixed patients and no need for multiple punctures made this blockage ideal for young pediatric patients. unfortunately, there are no adequate studies regarding peng block in patients younger than five years old. this study was carried out to assess ultrasound-guided peng block versus cb for their efficacy, safety and pain management in pediatric hip surgery.

Eligibility criteria:
inclusion criteria: * child aged 1- 7 years old * american society of anesthesiologists (asa) physical status i-ii * scheduled for elective hip surgery under general anesthesia exclusion criteria: * parents/guardians refusal to participate * known local anesthetic drug sensitivity, * bleeding disorders, * pre-existing infection at the block site, and * the presence of major cardiac, renal, or hepatic disorders.
assessment of hyperq signal for detecting ischemia during dobutamine stress ecg

Conditions: Myocardial Ischemia

Summary: the purpose of the study is to verify the ability of the hyperq signal to detect dobutamine induced ischemia. the gold standard for ischemia will be the results of angiography if performed, or echocardiographic imaging, which was performed during the test.

subjects referred for dobutamine stress echocardiography who will sign an informed consent form will go through the test. high resolution ecg from 12 leads will be recorded using bsp's hyperq system before, during and following the echo testing. this wil be done without interfering or affecting any aspect of the normal procedure. standard protocol will be used with standard test termination indications. the diagnostic stage will include analysis of the hyperq signal, aiming to classify results as ischemic or non-ischemic. the hyperq data will be compared to dse results which will be used as the "gold standard" for this study unless angiography results are obtained. an additional comparison evaluation will be performed to assess the advantage of the hyperq results on the st-changes results obtained from conventional ecg.in addition all recruited subjects will be followed for up to 12 months.during this period a phone call will be performed every 3 months to evaluate cardiac status, hospitalization and especially angiography procedures.

Eligibility criteria:
inclusion criteria: * subject referred to dobutamine stress echocardiography * subject signed informed consent exclusion criteria: * subjects with implantable pacemakers or defibrillators * subjects with wolff-parkinson-white syndrome

Keywords: hyperq ischemia dobutamine
the effects of n-acetylcysteine on performance and redox homeostasis

Conditions: Glutathione Metabolism Anemias

Summary: the main objective of the present study was to investigate whether n-acetylcysteine supplementation in individuals with low glutathione levels would confer ergogenic effects by replenishing glutathione levels and by reducing oxidative stress. towards this aim, investigators sought to exploit the large inter-individual variability in redox biomarker levels. more specifically, investigators screened 100 male participants for glutathione baseline levels in blood and formed three stratified groups according to this value (i.e., low, moderate and high; 12 individuals per group). after by-passing the regression to the mean artefact by performing a second glutathione measurement in the three aforementioned groups, investigators assessed both aerobic and anaerobic physical performance in order to acquire a more comprehensive view about the ergogenic effectiveness of the antioxidant treatment. this was accomplished by implementing three different whole-body physical performance tests (i.e., vo2max test, time trial and wingate), as opposed to most in vivo studies that either applied isolated body-part exercise tests (e.g., by isokinetic dynamometry) or performed a single exercise test (e.g., time-to-fatigue test). it was hypothesised, that data of the present investigation will bridge the chasm between the scientific (i.e., chronic antioxidant supplementation blunts exercise performance and adaptations) and the community-based (i.e., free radicals should anyway be counteracted by "protective" exogenous antioxidants) truths about the role of antioxidants as ergogenic aids. it was also hypothesised that the results will show that low glutathione levels are linked to decreased aerobic and anaerobic physical performance accompanied by increased levels of oxidative stress and that n-acetylcysteine supplementation will restore both performance and redox homeostasis. based on the findings of the present investigation, the widespread routine practice of consuming antioxidants during exercise training could be changed and the consumption of antioxidants would be restricted only for those who are deficient in glutathione.


Eligibility criteria:
inclusion criteria: * healthy male subjects who participated recreationally in physical activities less than 3 times per week. exclusion criteria: * subjects were excluded from the study, if they reported any musculoskeletal injury that would limit their ability to perform the exercise sessions. participants were asked to recall whether they had participated in regular resistance or aerobic training or in unaccustomed exercise during the period before the study entry. individuals who reported such activities were precluded from the study. smoking and consumption of antioxidant supplements the days prior to the study were additional exclusion criteria.
iron therapy for autosomal dominant hypophosphatemic rickets: a pilot project.

Conditions: Autosomal Dominant Hypophosphatemic Rickets

Summary: the purpose of the study is to gain a better understanding of the effect of iron on fibroblast growth factor 23 (fgf23) in the inherited disorder, autosomal dominant hypophosphatemic rickets (adhr). adhr is an inherited disorder in which the body makes too much fgf 23 and causes low blood phosphorus levels and bone problems such as rickets (bowed legs in children) or bone pain and weakness in adults. this study is to test whether or not giving iron helps correct the high fgf23 and there by correcting the phosphate problem.

iron will be provided in an open label treatment to all enrolled subjects. iron levels will be monitored in blood and doses adjusted with the target of getting the iron levels to or a little above 100 mcg/dl. the study will look to see if there is a decrease of fgf23 level. it will also look at how long does it take to decrease the level of fgf 23 and how long it takes for the serum and urine phosphate to normalize.

Eligibility criteria:
inclusion criteria: * fgf mutation in either arginine 176 or arginine 179 * able and willing to provide consent or have a parent that is able/willing to consent, if a minor * either serum iron \<50mcg/dl (regardless of phosphate or intact fgf23 concentration); or iron between 500 and 100mcg/dl with serum phosphorus value below 3.0mg/dl for adults or less than or equal to 0.5 mg/dl the lower limit of normal for age in children and intact fgf23 about 30pg/ml * age \>2 years * may be receiving treatment with phosphate and calcitriol, but must be willing to undergo dose adjustments by the investigators if iron resolves the phosphate wasting defect. exclusion criteria: * malignancy within the last 5 years, except treated squamous or basal cell skin carcinoma * terminal illness/hospice. * severe end-organ disease, e.g. cardiovascular, pulmonary, etc, which may limit ability to complete study. estimated gfr \<45ml/min/1.73m2, calculated using mdrd formula for adults or modified schwartz equation for children * pregnancy or plan on becoming pregnant

Keywords: adhr rickets hypophosphatemia
alcohol abuse or alcohol withdrawal: risk of latent scurvy

Conditions: Alcoholics

Summary: scurvy, or latent scurvy, may be underestimated in developed countries, but continue to be described, often as case report. little is known about the prevalence of vitamin c deficiency in a specific population as withdrawal alcoholics and about his possible consequences, latent scurvy. in an observational study, the investigators will evaluate prospectively the prevalence of vitamin c deficiency in alcoholic withdrawal patients, its correlation with latent scurvy, mainly tiredness and weakness, and the evolution of the latter at three months after oral vitamin c supplementation.

this study aims to examine: 1. the level of plasma vitamin c for patients that volunteered for alcohol withdrawal. measurement of vitamin c plasma level will be performed as soon as possible after the agreement as the discussion with the physician could lead to a change in dietary habits. it will be performed by high-pressure liquid chromatography (cerba laboratory, f-cergy pontoise) according to lee et al. 2. the correlation between plasma vitamin c level and clinical signs of scurvy, especially signs of latent scurvy like tiredness, leg pain, gums involvement, previously loss of healthy teeth. these signs will be recorded in a structured questionnaire during the first consultation, before knowing the laboratory result patient. all patients who are smoking will perform systematic otorhinolaryngology examination in search of cancer. other reasons for weakness will be searched by clinical anamneses, body examination, blood probe and abdominal ultrasound examination. 3. the decrease or disappearance of tiredness and/or purpura and/or gums involvement will be studied after vitamin c supplementation in patients whose vitamin c plasma determination is under normal levels and that don't have another explanation for their tiredness. patients will be evaluated after receiving 1 g oral vitamin c for at least three months. ethical considerations the study was approved by the institutional ethics committee of the clinic and was conducted in accordance with the principles of the declaration of helsinki. informed consent was obtained before entry study and each participant agreed to pay for the plasma vitamin c determination. dissemination findings findings for the present study will be reported in manuscripts that will be submitted for publication to a leading medical or nutrition journal in a appropriate field (i.e.alcoholism, nutrition). in addition, findings will be presented as abstracts, posters and presentations at conferences.

Eligibility criteria:
inclusion criteria: * patients who volunteered for alcohol detoxification even if they had prior complications of excessive alcohol consumption. * each patient provided written consent to the study and agreed to pay himself the determination of the plasma ascorbic level. exclusion criteria: * confusion or alcoholic coma.

Keywords: alcohol withdrawal scurvy vitamin c tiredness
apatinib combined with egfr-tki for advanced slow-progressed egfr-tki resistant nsclc

Conditions: NSCLC; Apatinib; EGFR-TKI

Summary: patients with advanced non-small cell lung cancer (nsclc) who progress slowly after epidermal growth factor receptor tyrosine kinase inhibitors（egfr-tki）resistance will be treated with apatinib and egfr-tki. the primary objective is the disease progression free survival of the patients.

patients with advanced non-small cell lung cancer (nsclc) who had treated with epidermal growth factor receptor tyrosine kinase inhibitors（egfr-tki） and progressed slowly because of resistance are underwent with apatinib mesylate and continuous egfr-tki. the primary objective is the disease progression free survival of the patients. the secondary goals are overall survival, duration of response, objective response rates, disease control rates, quality of life scores and drug safety. currently such patients are treated with egfr-tki continuously, but 3 months later, the disease will be progressed rapidly. this study will bring a new treatment that are more effective, less toxic and more convenient for nsclc-patients with egfr-tki resistance.

Eligibility criteria:
inclusion criteria: * pathologically confirmed advanced (stage iv) non-squamous, non-small cell lung cancer with measurable lesions * electronics coordinating grop（ecog）score：0-2 * expected survival over 3months * hemoglobin(hb)≥90 gram(g)/liter(l)；absolute neutrophil count(anc)≥1.5×109/l；platelet(plt)≥80×109/l；total-bilirubin（t-bil）\<1.5 upper limit of normal value（uln）；alanine aminotransferase（alt）and aspartate aminotransferase（ast）\<2.5 uln；cr≤1.25uln exclusion criteria: * brain metastases, meningococcal meningitis, patients with spinal cord compression with evidence of imaging (computed tomography（ct） / magnetic resonance imaging （mri）, et cetera（etc.）); * uncontrolled hypertension (systolic blood pressure（bp）≥140 millimeter mercury column（mmhg） or diastolic bp ≥90 mmhg, despite optimal drug therapy); * hemorrhoid dysfunction (inernational standard ratio(inr)\> 1.5 or prothrombin time (pt)\> uln + 4 seconds or activated partial thromboplastin(aptt)\> 1.5 uln) with bleeding tendency or undergoing thrombolytic or anticoagulant therapy; * patients treated with anticoagulants or vitamin k antagonists such as warfarin, heparin, or the like; * patients underwent major surgery or severe traumatic injury, fracture or ulcer in 4 weeks before study; * urine routine urine protein ≥ +++, or confirmed 24 hours urinary protein content ≥ 1.0 g;

Keywords: apatinib egfr-tki resistance slowly progress
clinical specimens testing program of dengue antigen detection reagents

Conditions: Dengue Fever

Summary: dengue virus serological reagent, included antigen and antiserum, is a serum test for identification of serum antibodies to dengue virus.

the developed assay helps to diagnose diseases caused by this virus and to provide information on disease epidemiology. this virus is mainly transmitted by mosquito bites to people and will make flu-like symptoms, including fever, fatigue, cough and headache, which can cause severe hemorrhagic dengue.

Eligibility criteria:
inclusion criteria:a total of 95 cases and 100 controls (suspected cases(\>50 %) and normal subjects) are expected to enroll. 1. case group: adults having a medical visit or admission due to dengue / dengue hemorrhagic fever / dengue shock syndrome, and medical care of by (defined by cdc). any of the following positive test results for the case of 100 adults. 1. clinical specimens (blood) isolated and identified dengue virus. 2. clinical specimens positive for molecular detection of nucleic acids. 3. serological antigen (referring to non-structural proteins of dengue virus non-structural protein 1, ns1) testing positive (based on the test of bio-rad dengue ns1 ag strip). 4. paired serum (restored period and acute phase), the dengue virus specific immunoglobulin m or immunoglobulin g antibodies or negative or ≧ 4 times increase. 2. suspected cases: adults having medical visits or admissions due to infectious disease, but their ns1 (based on the test of bio-rad dengue ns1 ag strip), immunoglobulin g,immunoglobulin m, real time-polymerase chain reaction testing were negative. 3. control group: adults without having medical visits or admissions due to fever. - exclusion criteria:non-adult case -